Page 2 - Gary Gemignani News Today : Breaking News, Live Updates & Top Stories | Vimarsana

NEW YORK, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Laidlaw Venture Partners (“LVP”), the venture capital arm of Laidlaw & Company (UK) Ltd., today announced...

Investegate announcements from Acacia Pharma Group plc, Acacia Pharma Announces Submission and Validation of Marketing Authorization Application for BARHEMSYS® (amisulpride injection) in Major European Markets

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and...

™ (remimazolam injection) US commercial rights to BYFAVO were in-licensed from Cosmo Pharmaceuticals NV (“Cosmo”) in January 2020 and it was approved in July 2020 for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less which make up around 40m procedures a year in the US, including 25m gastro-intestinal procedures 3 for an estimated >$1.5 billion annual total addressable market 4. References 1. Calculations based on available procedural data, applied Compound Annual Growth Rate and quantitative market research responses as foll...

, 07:00 CEST : Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, is proud to be named a new Industry Supporter of the American Society of Anesthesiologists (“ASA” or the “Society”). Launched in 2010, ASA’s Industry Supporter Program is limited to ten organizations. Participation is intended for c...